Modeling the dynamics of immunological synapses informs pharmacodynamics and treatment resistance to bispecific T cell engagers.

A mathematical model of osteoporosis explains why the sequence of osteoporosis medications matters for short-term and long-term treatment success.

Most chloroquine regimens trialled for the treatment of COVID19 will not result in life-threatening cardiovascular toxicity.

Biological and pharmacokinetic studies indicate that the anti-tubercular drug, delamanid, could be repurposed for the treatment of visceral leishmaniasis.

Erastin and sorafenib inhibit system x_c^- and induce ER stress, suggesting these may be useful tools for probing the functions of system x_c^- and its role in inducing ER stress and ferroptosis.

The currently recommended adult dose of tafenoquine is insufficient for radical cure in all adults.

Increasing validity should be a priority when deciding which preclinical experiments to replicate and when performing replications.

The number and effects of mutations leading to full drug resistance crucially determine treatment failure probability and should be used to inform antimicrobial treatment strategies with regard to avoidance of resistance emergence.

GDC-0810 is a novel, orally bioavailable SERD that exhibits robust pre-clinical activity in models of ER+ breast cancer, including models of tamoxifen resistance, and those that express the ERα mutations, ER.Y537S and ER.D538G.

Anti-asprosin monoclonal antibodies, a promising pharmacotherapy for the treatment of metabolic syndrome-associated hyperglycemia, obesity, and dyslipidemia.